- Home
- PBM vs ATXI Comparison
PBM vs ATXI Comparison
Compare PBM & ATXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBM
- ATXI
- Stock Information
- Founded
- PBM 1994
- ATXI 2015
- Country
- PBM Canada
- ATXI United States
- Employees
- PBM N/A
- ATXI N/A
- Industry
- PBM
- ATXI Biotechnology: Pharmaceutical Preparations
- Sector
- PBM
- ATXI Health Care
- Exchange
- PBM NYSE
- ATXI Nasdaq
- Market Cap
- PBM 2.8M
- ATXI 3.0M
- IPO Year
- PBM N/A
- ATXI 2017
- Fundamental
- Price
- PBM $1.53
- ATXI $1.84
- Analyst Decision
- PBM
- ATXI
- Analyst Count
- PBM 0
- ATXI 0
- Target Price
- PBM N/A
- ATXI N/A
- AVG Volume (30 Days)
- PBM 2.2M
- ATXI 26.2K
- Earning Date
- PBM 02-02-2025
- ATXI 11-14-2024
- Dividend Yield
- PBM N/A
- ATXI N/A
- EPS Growth
- PBM N/A
- ATXI N/A
- EPS
- PBM N/A
- ATXI N/A
- Revenue
- PBM N/A
- ATXI N/A
- Revenue This Year
- PBM N/A
- ATXI N/A
- Revenue Next Year
- PBM N/A
- ATXI N/A
- P/E Ratio
- PBM N/A
- ATXI N/A
- Revenue Growth
- PBM N/A
- ATXI N/A
- 52 Week Low
- PBM $1.51
- ATXI $1.60
- 52 Week High
- PBM $945.15
- ATXI $26.48
- Technical
- Relative Strength Index (RSI)
- PBM 20.19
- ATXI 44.82
- Support Level
- PBM $1.85
- ATXI $1.80
- Resistance Level
- PBM $2.11
- ATXI $1.88
- Average True Range (ATR)
- PBM 0.55
- ATXI 0.13
- MACD
- PBM 0.07
- ATXI -0.01
- Stochastic Oscillator
- PBM 0.80
- ATXI 40.70
About PBM PSYENCE BIOMEDICAL LTD
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
About ATXI Avenue Therapeutics Inc.
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.